The UK Government has recently committed to spending £3.5 million to help develop new treatments for gonorrhoea and to make them available in low and middle-income countries.
This investment is part of a continued partnership with the Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Global Antibiotic Research and Development Partnership (GARDP).
The investment aims to enable global access to gonorrhoea treatment, especially in low- and middle-income countries where the burden of antimicrobial resistance (AMR) is greatest, and to fund GARDP’s development of a new oral antibiotic, zoliflodacin, which is now in the last stage of clinical trials.
Zoliflodacin is one of the few antibiotics in development which specifically treats gonorrhoea, which is significant as treatments for gonorrhoea are becoming less effective. There have been cases of gonorrhoea developing resistance to recommended treatments, including in the UK.
Gonorrhoea is among the most common sexually-transmitted infections (STIs), with an estimated 87 million new cases globally every year. The STI can have severe consequences on public health and, when left untreated, serious consequences for reproductive health as well as increased risk of transmission of HIV and other STIs.
Source: Department of Health and Social Care (DHSC), 31 October 2019